Advertisement

Elevated HDL is a risk factor for recurrent coronary events in a subgroup of non-diabetic postinfarction patients with hypercholesterolemia and inflammation

      Abstract

      Recent studies demonstrate important roles for inflammation in development of atherosclerosis with current attention focusing on interactions of inflammation with traditional lipoprotein risk factors. Since the nature of such relationships is largely unknown, we sought to investigate interactions of inflammation with hyperlipidemia in generating cardiovascular risk in a way that would allow recognition of such interactions whether anticipated or not. Thus, we searched for subgroups at high risk for recurrent coronary events in 767 non-diabetic postinfarction patients using an exploratory three-dimensional graphical screening technique with previously established factor analysis-derived inflammatory and lipoprotein-related factors. Results indicated a high-risk patient subgroup defined by factor interaction that was best characterized clinically by high levels of C-reactive protein (CRP) and total cholesterol. Kaplan–Meier and Cox multivariate analysis confirmed high-risk. Additionally, within-subgroup risk related to metabolic, inflammatory, and thrombogenic blood markers was assessed using Cox analysis with results showing only elevated HDL as a significant and independent predictor of risk with hazard ratio, 2.24 (95% CI; 1.12, 4.49; p = 0.023). We conclude that in non-diabetic postinfarction patients, elevated HDL is predictive of risk of recurrent coronary events within a subgroup of patients characterized by simultaneous elevations in serum CRP and total cholesterol.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ridker P.M.
        • Cannon C.P.
        • Morrow D.
        • et al.
        C-reactive protein levels and outcomes after statin therapy.
        N Engl J Med. 2005; 352: 20-28
        • Nissen S.E.
        • Tuzcu E.M.
        • Schoenhagen P.
        • et al.
        Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.
        N Engl J Med. 2005; 352: 29-38
        • Moss A.J.
        • Goldstein R.E.
        • Marder V.J.
        • et al.
        Thrombogenic factors and recurrent coronary events.
        Circulation. 1999; 99: 2517-2522
        • Corsetti J.P.
        • Zareba W.
        • Moss A.J.
        • et al.
        Metabolic syndrome best defines the multivariate distribution of blood variables in postinfarction patients.
        Atherosclerosis. 2003; 171: 351-358
        • Corsetti J.P.
        • Zareba W.
        • Moss A.J.
        • Sparks C.E.
        Apolipoprotein B determines risk for recurrent coronary events in postinfarction patients with metabolic syndrome.
        Atherosclerosis. 2004; 177: 367-373
        • Corsetti J.P.
        • Zareba W.
        • Moss A.J.
        • Sparks C.E.
        Serum glucose and triglyceride determine high-risk subgroups in non-diabetic postinfarction patients.
        Atherosclerosis. 2005; 183: 293-300
        • Rainwater D.L.
        Electrophoretic separation of LDL and HDL subclasses.
        Meth Mol Biol. 1998; 110: 137-151
        • Ridker P.M.
        • Glynn R.J.
        • Hennekens C.H.
        C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction.
        Circulation. 1998; 97: 2007-2011
        • Ridker P.M.
        • Rifai N.
        • Rose L.
        • Buring J.E.
        • Cook N.R.
        Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.
        N Engl J Med. 2002; 347: 1557-1565
        • Bassuk S.S.
        • Nader R.
        • Ridker P.M.
        High-sensitivity C-reactive protein: clinical importance.
        Curr Probl Cardiol. 2004; 29: 439-493
        • Ridker P.M.
        High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit.
        Am Heart J. 2004; 148: S19-S26
        • De Backer G.
        • de Bacquer D.
        • Kornitzer M.
        Epidemiological aspects of high density lipoprotein cholesterol.
        Atherosclerosis. 1998; 137: S1-S6
        • Jeppesen J.
        • Hein H.O.
        • Suadicani P.
        • Gyntelberg F.
        Triglyceride concentration and ischemic heart disease.
        Circulation. 1998; 97: 1029-1036
        • von Eckardstein A.
        • Schulte H.
        • Assmann G.
        Increased risk of myocardial infarction in men with both hypertriglyceridemia and elevated HDL cholesterol.
        Circulation. 1999; 99: 1925
        • Bittner V.
        • Simon J.A.
        • Fong J.
        • et al.
        Correlates of high HDL cholesterol among women with coronary heart disease.
        Am Heart J. 2000; 139: 288-296
        • Shimoni N.
        • Kaplan M.
        • Keidar S.
        Cardiovascular diseases in patients with high levels of plasma high density lipoprotein: association with increased plasma oxidative state.
        Israel Med Assoc J. 2003; 5: 702-705
        • Agerholm-Larsen B.
        • Nordestgaard B.G.
        • Steffensen R.
        • Jensen G.
        • Tybjaerg-Hansen A.
        Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene.
        Circulation. 2000; 101: 1907-1912
        • Gnasso A.
        • Motti C.
        • Irace C.
        • et al.
        The ARG allele in position 192 of PON1 is associated with carotid atherosclerosis in subjects with elevated HDLs.
        Atherosclerosis. 2002; 164: 289-295
        • deLemos A.S.
        • Wolfe M.L.
        • Long C.J.
        • Sivapackianathan R.
        • Rader D.J.
        Identification of genetic variants in endothelial lipase in persons with elevated high-density lipoprotein cholesterol.
        Circulation. 2002; 106: 1321-1326
        • Ma K.
        • Cilingiroglu M.
        • Otvos J.D.
        • et al.
        Endothelial lipase is a major genetic determinant for high-density lipoprotein concentration, structure, and metabolism.
        PNAS. 2003; 100: 2748-2753
        • Broedl U.C.
        • Jin W.
        • Rader D.J.
        Endothelial lipase: a modulator of lipoprotein metabolism upregulated by inflammation.
        Trends Cardiovasc Med. 2004; 14: 202-206
        • Grundy S.M.
        • Vega G.L.
        • Otvos J.D.
        • Rainwater D.L.
        • Cohen J.C.
        Hepatic lipase activity influences high density lipoprotein subclass distribution in normotriglyceridemic men: genetic and pharmacological evidence.
        J Lipid Res. 1999; 40: 229-234
        • Ruel I.L.
        • Couture P.
        • Cohn J.S.
        • et al.
        Evidence that hepatic lipase deficiency in humans is not associated with proatherogenic changes in HDL composition and metabolism.
        J Lipid Res. 2004; 45: 1528-1537
        • Van Lenten B.J.
        • Navab M.
        • Shih D.
        • Fogelman A.M.
        • Lusis A.J.
        The role of high-density lipoproteins in oxidation and inflammation.
        Trends Cardiovasc Med. 2001; 11: 155-161
        • Navab M.
        • Berliner J.A.
        • Subbanagounder G.
        • et al.
        HDL and the inflammatory response induced by LDL-derived oxidized phospholipids.
        Arterioscler Thromb Vasc Biol. 2001; 21: 481-488
        • Navab M.
        • Hama S.Y.
        • Ready S.T.
        • et al.
        Oxidized lipids as mediators of coronary heart disease.
        Curr Opin Lipidol. 2002; 13: 363-372
        • Kovanen P.T.
        • Pentikainen M.O.
        Circulating lipoproteins as proinflammatory and anti-inflammatory particles in atherogenesis.
        Curr Opin Lipidol. 2003; 14: 411-419
        • Zheng L.
        • Nukuna B.
        • Brennan M.L.
        • et al.
        Apolipoprotein A–I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease.
        J Clin Invest. 2004; 114: 529-541
        • Bergt C.
        • Pennathur S.
        • Fu X.
        • et al.
        The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport.
        PNAS. 2004; 101: 13032-13037
        • Pennathur S.
        • Bergt C.
        • Shao B.
        • et al.
        Human atherosclerotic intima and blood of patients with established coronary artery disease contain high density lipoprotein damaged by reactive nitrogen species.
        J Biol Chem. 2004; 279: 42977-42983